Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Pilot Trial of Autologous T Cells Engineered to Express Anti-CD19 Chimeric Antigen Receptor (CART19) in Combination With Ibrutinib in Patients With Relapsed or Refractory CD19+ CLL or SLL

NCT02640209 is registered in ClinicalTrials.gov with University of Pennsylvania as lead sponsor.

NCT NCT02640209
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02640209 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Pilot Trial of Autologous T Cells Engineered to Express Anti-CD19 Chimeric Antigen Receptor (CART19) in Combination With Ibrutinib in Patients With Relapsed or Refractory CD19+ CLL or SLL
Lead sponsor
University of Pennsylvania
Phase
Phase 1
Overall status
Terminated
Start date
January 29, 2016
Completion date
July 16, 2019
Enrollment
20 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

lymphocytic leukemia (cll) or small lymphocytic lymphoma (sll)